QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Alphatec Holdings, Inc. (ATEC)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore is 2 (below the required floor of 3; shadow flag false, so the SHADOW_FST9 branch does not apply) — the company failed the upstream qualitative screen after the Q3 miss/guidance cut and the law-firm solicitation wave, and no chart pattern overrides that; the chart independently offers no tradable long (price below sma20/50/200 and ema9/21, MACD -0.85 < 0, ADX 28.4 down-trend, oversold bounce only).

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

Alphatec is a medtech company specializing in spine-surgery devices. It is undergoing a multi-year turnaround with recent improvements in revenue growth and operating cash flow, despite remaining GAAP loss-making.

Fundamental

fair
Fundamental3
Mixed fundamentals

Alphatec shows revenue growth and positive cash flow but remains GAAP loss-making with high leverage and negative equity.

Mixed fundamentals: the spine-device business is inflecting - 25% FY2025 revenue growth, positive operating cash flow, and a first positive operating quarter in Q3 2026 - but the company remains GAAP loss-making with negative stockholders' equity, roughly 16x net debt to EBITDA and negative interest coverage. A May 2026 refinancing removed the near-term maturity wall and cut borrowing costs materially. Cheap EV/Sales and a wide DCF-to-price gap are offset by a rich EV/EBITDA and a mechanical distress-zone Altman reading. Insiders are buying near the current quote. Watchlist-quality turnaround rather than a clean buy.

Sentiment

weak
Sentiment2
Bearish sentiment

Sentiment is negative following a guidance cut, downgrades, and legal solicitations, with no near-term catalysts.

Dominant driver is the announced but bearish Q3 2026 print (revenue $221.2M vs. $225.2M and adjusted EPS $0.09 vs. $0.10 estimates, FY2026 revenue guidance cut to ~$862M on a temporary international supply constraint, lower biologics attachment and softer thoracolumbar volumes) plus the sell-side reaction to it — a BMO downgrade to Market Perform with a $12 to $8 target and Wells Fargo/Needham target cuts from $14 to $12 — with media sentiment determinately deteriorating from a +0.18 baseline to -0.16 in the 14-day window (a ~0.34 swing) and no forward-dated catalyst inside 30 days. The Red-Flag Screen shows no severe flag, but a moderate conflicting-catalyst cap applied because a single ~$243K director purchase sits bullish against the bearish earnings and downgrade legs — a de minimis offset that leaves the setup weak rather than genuinely mixed.

Technical

weak
Technical2
Downtrend with bounce

The stock is in a downtrend with only an oversold bounce, lacking a tradable bullish setup.

Score 2/5 — the chart is a post-earnings downtrend with only an oversold bounce in progress. Last close 7.365 sits below sma20 9.38, sma50 9.84, sma200 10.20, ema9 7.90 and ema21 8.86; MACD is -0.85 vs signal -0.56 (histogram -0.29) and ADX at 28.39 confirms a strong directional (down) trend. RSI 35.90 and Williams %R -89.70 show oversold conditions and price is ticking up off the 2026-10-30 post-earnings low of 6.81 (+4% intraday), but this is bounce-only price action with no reclaimed moving average and no momentum cross — not a tradable bullish structure. Even setting the qualitative block aside, a pullback limit here would be countertrend (price < sma50 with macdLine < 0; also below a declining sma200 with sma50 < sma200 and no reclaim), and a breakout stop has no settled base to anchor above the post-gap range.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.